Ryan D. Chow, MD

Ryan D. Chow, MD, is a hematology/oncology fellow at Penn Medicine, the University of Pennsylvania Health System.

Articles by Ryan D. Chow, MD

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

ByRonac Mamtani, MD, MSCE,Ramy Sedhom, MD,Ryan D. Chow, MD

February 5th 2026

Ramy Sedhom, MD, Ryan Chow, MD, and Ronac Mamtani, MD, MSCE, discuss dose reducing enfortumab vedotin to improve tolerability, without in patients with bladder cancer

Dr Chow on the Benefits of Upfront Dose Reduction for Enfortumab Vedotin in Urothelial Cancer

ByRyan D. Chow, MD

February 3rd 2026

Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.

Latest Updated Articles

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE
February 5th 2026

Ryan D. Chow, MD

Articles by Ryan D. Chow, MD

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

Dr Chow on the Benefits of Upfront Dose Reduction for Enfortumab Vedotin in Urothelial Cancer

Latest Updated Articles

Trending on OncLive

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

The OncFive: Top Oncology Articles for the Week of 6/28

Five Under 5: Top Oncology Videos for the Week of 6/28

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera